Seres Therapeutics, INC DEF 14A proxy statements

Seres Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9th, to address key corporate matters including director elections and equity plan amendments.

Seres Therapeutics files a supplement to its proxy statement to correct an error in the calculation of total shareholder return (TSR) within the Executive Compensation section.

Seres Therapeutics is asking stockholders to approve a reverse stock split, an amended incentive award plan, and other corporate governance changes at its upcoming annual meeting.

Seres Therapeutics announces positive topline results from its SER-155 Phase 1b study, demonstrating a significant reduction in bloodstream infections and antibiotic use in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Seres Therapeutics is selling its VOWST microbiome therapeutic business to Socit des Produits Nestl S.A. for an upfront payment and potential milestone payments, plus a profit share period.

Seres Therapeutics discussed the sale of Vowst to Nestl, the upcoming SER-155 data readout, and the potential of its microbiome therapeutics platform at the Canaccord Genuity Growth Conference.

Seres Therapeutics announces the sale of its VOWST assets to Nestle Health Science for $155 million upfront, plus future payments, to focus on advancing its pipeline of live biotherapeutics.

Seres Therapeutics reports its second quarter 2024 financial results, highlights the sale of its VOWST business to Nestl, and anticipates extending its operational runway into the fourth quarter of 2025.

Seres Therapeutics announces the sale of its VOWST assets and commercial rights to Nestle for a combination of upfront payments, equity investment, and potential milestone payments, aiming to strengthen its balance sheet and advance its pipeline.

Seres Therapeutics is seeking stockholder approval for a proposed asset purchase agreement with Société des Produits Nestlé S.A.

Seres Therapeutics has signed an asset purchase agreement with Nestle for VOWST, aimed at bolstering its financial position and continuing its focus on developing therapies for life-threatening infections.

Seres Therapeutics has entered into an agreement to sell its VOWST microbiome therapeutic business to Socit des Produits Nestl S.A. for an upfront payment of $100 million and potential milestone payments totaling up to $335 million.

Seres Therapeutics is selling its VOWST business to Nestl Health Science for an upfront payment and potential milestone payments, allowing Seres to focus on its pipeline and extend its cash runway.

Seres Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on April 4, 2024, outlining proposals including director elections, auditor ratification, executive compensation approval, and an increase in authorized common stock.